Cannabis Conundrum: Demonstrating “Accepted Medical Use” in a Restricted Research Environment

October 7, 2020
Delia Deschaine
Federal
0 Comments

By Delia Ann Deschaine and Megan Robertson U.S. cannabis businesses operate in an increasingly complex legal and regulatory environment. Many, if not most, of those complexities stem from marijuana’s classification in Schedule I of the federal Controlled Substances Act. That…

FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level

August 25, 2020
Agustin Rodriguez
Hemp Policy & Legal
0 Comments

By Agustin Rodriguez and Dascher Pasco On Tuesday, July 21, 2020, the U.S. Food and Drug Administration (FDA) issued “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry.” This is the first draft guidance from the…